What is Syantra?
Syantra operates at the intersection of biotechnology and precision medicine, primarily through its flagship Onco-ID platform. By monitoring systemic shifts within the human immune response, the company provides a non-invasive, highly sensitive method for identifying oncological markers long before traditional screening methods. This diagnostic approach represents a significant shift from reactive to proactive healthcare, targeting clinical research partners and healthcare providers who require high-fidelity data to improve patient outcomes. By integrating advanced molecular diagnostics with clinical utility, Syantra is establishing a new standard for early intervention in cancer care.
How much funding has Syantra raised?
Syantra has raised a total of $6.6M across 1 funding round:
Series A
$6.6M
Series A (2024): $6.6M with participation from WealthPoint at CG Wealth Management
Key Investors in Syantra
WealthPoint at CG Wealth Management
WealthPoint is a boutique wealth management firm that offers holistic financial planning tailored to the unique needs of families, business owners, and retirees, focusing on generational wealth preservation and comprehensive financial strategies.
What's next for Syantra?
Following this major enterprise-level funding, Syantra is expected to prioritize the expansion of its clinical study pipeline and the scaling of its commercial operations. The strategic deployment of this capital will likely focus on strengthening regulatory pathways and deepening collaborations with research institutions to validate the Onco-ID platform across broader patient demographics. As the company transitions into a more mature growth phase, the focus will shift toward market penetration and the integration of its diagnostic tests into standard clinical workflows, ultimately aiming to reduce the global burden of late-stage cancer diagnoses through technological innovation.
See full Syantra company page
